PROTACs
-
PROTACs Related Products (453)
Related Products (453)
-
AD4
0 ImagesAD4 is an artemisinin derivative that is a proteolytic targeting chimera (PROTAC) targeting PCLAF. AD4 can effectively degrade PCLAF in RS4;11 cells (IC50: 0.6 nM), thereby activating the p21/Rb axis and exerting anti-tumor activity. AD4 also prolonged survival of RS4;11-transplanted NOD/SCID mice, with in vivo efficacy.
-
SMART1
0 ImagesCat. No.: HY-W998345Purity: 99.87%
-
SJF-1528 hemihydrate
0 ImagesCat. No.: HY-131864APurity: 98.90%SJF-1528 (PROTAC 1) hemihydrate is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutant EGFR in HeLa cells. SJF-1528 hemihydrate also degrades HER2. SJF-1528 hemihydrate promotes ubiquitination and degradation of EGFR and can be used in breast cancer research.
-
(Rac)-EBET-1055
0 ImagesCat. No.: HY-161346ACAS No.: 3031540-65-2(Rac)-EBET-1055 is the racemate of EBET-1055 (HY-161346). EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures.
-
PROTAC ERK5 degrader-1
0 ImagesPROTAC ERK5 degrader-1 (compound 2) is a bifunctional ERK5 PROTAC degrader. PROTAC ERK5 degrader-1 induces ERK5 degradation via VHL-mediated proteasome pathway in MOLT-4 cells. PROTAC ERK5 degrader-1 can be used for the study of a disease or disorder characterized by aberrant ERK5 activity, such as acute lymphoblastic leukemia.
-
PROTAC TTK degrader-1
0 ImagesPROTAC TTK degrader-1 is a PROTAC degrader targeting Threonine Tyrosine Kinase (TTK), with a DC50 of 5.8 nM in HCT-116 cells and 1.7 nM in COLO-205 cells. PROTAC TTK degrader-1 induces the formation of a ternary complex with TTK and the CRBN E3 ubiquitin ligase, triggering proteasome-mediated degradation. PROTAC TTK degrader-1 exhibits activity against colon cancer cells and shows anti-tumor activity in a colon cancer xenograft mouse model. It can be used in colon cancer-related research.
-
PVD-06
0 ImagesPVD-06 is a selective PROTAC PTPN2 degrader with a DC50 of 217 nM (selectivity index >60-fold over PTP1B). PVD-06 induces PTPN2 degradation via a VHL-, ubiquitin, and proteasome-dependent pathway. PVD-06 can promote T cell activation and amplify IFN-γ-mediated anticancer activity. PVD-06 can be used to further investigate PTPN2 in diseases such as leukemia and melanoma.
-
YN14
0 ImagesCat. No.: HY-155356Purity: 99.08%YN14 is a KRASG12C proteolysis targeting chimera (PROTAC). YN14 is highly potent and selective KRASG12C degrader and induces a stable KRASG12C: YN14: VHL ternary complex with low binding free energy (ΔG). YN14 has antiproliferative effects and significantly inhibits KRASG12C-mutant cancer cell growth. YN14 leads to tumor regression with tumor growth inhibition (TGI%) rates more than 100 % in the MIA PaCa-2 xenograft model.
-
dBRD4-BD1
0 ImagesdBRD4-BD1 is a selective and durable BRD4 degrader with an DC50 value of 280 nM (Dmax=77%). dBRD4-BD1 upregulates BRD2/3 protein level and shows low cytotoxicity than iBRD4-BD1.
-
PROTAC SOS1 degrader-1 TFA
0 ImagesCat. No.: HY-145737APurity: 98.38%PROTAC SOS1 degrader-1 TFA is a degrader of SOS1 PROTAC, with a DC50 of 98.4 nM and a Kd value of 44 nM. PROTAC SOS1 degrader-1 TFA induces the formation of a ternary complex with SOS1 and the VCB E3 ubiquitin ligase complex, thereby promoting the ubiquitination and proteasomal degradation of SOS1. PROTAC SOS1 degrader-1 TFA reduces KRAS-GTP levels, inhibits the phosphorylation of ERK in the RAS-RAF-MEK-ERK pathway, and suppresses the proliferation of cancer cells carrying KRAS mutations. PROTAC SOS1 degrader-1 TFA inhibits tumor growth in mouse xenograft models. PROTAC SOS1 degrader-1 TFA can be used for the research of KRAS-driven cancers.
-
LZ-07
0 ImagesCat. No.: HY-172590Purity: 98.27%LZ-07 is a IRAK4 PROTAC degrader (DC50 = 1.14 nM). LZ-07 leads to marked suppression of cytokines including IL-6, IL-1β, TNF-α, and IL-10 upon degradation of IRAK4. LZ-07 can be studied in research for autoimmune diseases (Pink: IRAK4 ligand (HY-172591); Blue: CRBN ligand (HY-34590); Black: linker (HY-B0149); CRBN ligand + linker: HY-172593).
-
Homo-BacPROTAC7 TFA
0 ImagesCat. No.: HY-153572AHomo-BacPROTAC7 TFA is a PROTAC protein degrader targeting ClpC1/ClpC2 with a Kd of 0.5-2.5 nM for both targets. Homo-BacPROTAC7 (TFA) acts as a bactericidal agent, induces killing of pathogenic mycobacteria, retains activity against dormant-like mycobacterial cells with reduced intracellular ATP levels, and shows elevated antibiotic potency relative to its parent monomer. Homo-BacPROTAC7 (TFA) can be used for the research of tuberculosis.
-
PROTAC PD-L1 degrader-2
0 ImagesCat. No.: HY-162972CAS No.: 2995357-09-8PROTAC PD-L1 degrader-2 is a PD-L1 PROTAC degrader with an IC50 of 197.4 nM and a Kd of 301 nM. PROTAC PD-L1 degrader-2 induces PD-L1 endocytosis, drives degradation via the proteasomal and lysosomal pathways, and inhibits the PD-1/PD-L1 interaction. As an immune activator, PROTAC PD-L1 degrader-2 increases the levels of CD4+, CD8+, granzyme B and perforin. PROTAC PD-L1 degrader-2 can be used in studies related to colon cancer immunology.
-
KT-474 hydrochloride
0 ImagesSynonyms: KYM-001 hydrochloride; PROTAC IRAK4 degrader-7 hydrochloride
